Irifrin BK eye drops 2.5%, 0.4 ml, 15 pieces

Irifrin BK eye drops - adrenomimetic. It has a direct stimulating effect mainly on α-adrenergic receptors.

When systemic application causes a narrowing of arterioles, increases OPSS and blood pressure. Cardiac output does not change or decrease, which is associated with reflex bradycardia (increased vagal tone) in response to arterial hypertension. Phenylephrine raises blood pressure not as dramatically as norepinephrine and epinephrine, but it lasts longer. This, apparently, is due to the fact that phenylephrine is more stable and does not collapse under the influence of COMT.

With topical application phenylephrine has a pronounced vasoconstrictive effect, causes mydriasis, can lower the intraocular pressure with open-angle glaucoma.

In average therapeutic doses, it practically does not affect the central nervous system.

Pharmacokinetics

After ingestion, phenylephrine is poorly absorbed from the digestive tract. Metabolized with the participation of MAO in the intestinal wall and with the "first passage" through the liver. Bioavailability of phenylephrine is low.

After topical application, it undergoes systemic absorption

Indications:

• Iridocyclitis (for the prevention of the appearance of posterior synechia and reduction of exudation from the iris).
• Expansion of the pupil in ophthalmoscopy and other diagnostic procedures necessary to monitor the state of the posterior segment of the eye, with laser interventions on the fundus and vitreoretinal surgery.
• Conducting a provocative test in patients with a narrow anterior chamber angle profile and suspicion of occlusive glaucoma.
• Differential diagnosis of superficial and deep injection of the eyeball.
• Syndrome of "red eye" (to reduce hyperemia and irritation of the mucous membrane of the eye).
• Prevention of asthenopia and spasm of accommodation in patients with high visual load.
• Treatment of false myopia (spasm of accommodation) and prophylaxis of the progres- sion of true myopia in patients with high visual load.

Contraindications:

• Hypersensitivity to the components of the drug.
• Narrow-angle or angle-closure glaucoma.
• Arterial hypertension in combination with ischemic heart disease "with aortic aneurysm, atrioventricular blockade of I - III degree, arrhythmia.
• Tachycardia.
• Diabetes mellitus type I in the anamnesis.
• Permanent intake of monoamine oxidase inhibitors, tricyclic antidepressants, antihypertensive drugs.
• Additional expansion of the pupil during surgical operations in patients with impaired integrity of the eyeball, as well as in violation of tear production.
• Reduced body weight in newborns.
• Hyperthyroidism.
• Hepatic porphyria.
• Congenital deficiency of glucose-6-phosphate dehydrogenase.
• The period of breastfeeding.

Carefully:

• In patients with type II diabetes - an increased risk of increasing blood pressure.
• In elderly patients - increased risk of reactive miosis.
• Exceeding the recommended dose of 2.5% solution in patients with trauma, eye disease or its appendages, in the postoperative period, or with reduced tear production can lead to an increase in the absorption of phenylephrine and the development of systemic side effects.
• Because of what causes conjunctival hypoxia - in patients with sickle cell anemia, with contact lenses, after surgical interventions (decreased healing).
• At a cerebral atherosclerosis.
• With long-term bronchial asthma.

Suggested Use:

When conducting ophthalmoscopy, single instillations of 2.5% Irifrin BK solution are used. As a rule, to create mydriasis it is enough to administer 1 drop of 2.5% solution of Irifrin BK into the conjunctival sac.

Maximum Mydriaz is reached after 15-30 minutes and remains at a sufficient level for 1-3 hours. If it is necessary to maintain mydriasis for a long time, after 1 hour, the repeated instillation of Irifrin BK is possible.

For diagnostic procedures:

• As a provocative test, patients with a narrow anterior chamber angle profile and suspicion of occlusive glaucoma are instilled with 1 drop of the drug once. If the difference between the values of intraocular pressure before instillation of IrifrinavBK and after dilating the pupil is from 3 to 5 mm Hg. the provocative test is considered positive.
• For differential diagnosis of the type of injection of the eyeball, 1 drop of the drug is instilled once: if 5 minutes after instillation there is a narrowing of the vessels of the eyeball, the injection is classified as superficial, while maintaining the redness of the eye, it is necessary to carefully examine the patient for the presence of iridocyclitis or scleritis, expansion of deeper lying vessels.

With iridocyclites

• To prevent the development and rupture of the already formed posterior synechia and to reduce exudation in the anterior chamber of the eye, 1 drop of the drug is instilled in the conjunctival sac of the diseased eye 2-3 times a day 5-10 days depending on the severity of the disease.

At schoolboys

• With myopia of weak degree. For the prevention of spasm of accommodation in the period of high visual load 1 drop Irifrin BK is buried in the evening before bedtime.
• With progressive myopia of medium degree
• 3 times a week in the evening before bedtime.

With emmetropia

• In the daytime, depending on the load. At a hypermetropia with a tendency to a spasm of accommodation at a high visual load. Bury in the evening Irifrin BC in combination with a 1% solution of cyclopentolate. Irritin BK is instilled in the usual visual load 3 times a week in the evening before going to sleep.

In the treatment of false and true myopia

• One drop of Irifrin BC is applied in the evening before bedtime 2-3 times a week for a month.

Packaging:

• Comes in original packaging. Item is brand new and unopened.

Storage:

• Keep away from direct sunlight.
• Keep locked and away from children.
• Store in dry place at room temperature.
• Do not exceed storage temperature higher than 25 C

Important notice- the outer box design may vary before prior notice!